{
    "clinical_study": {
        "@rank": "11614", 
        "arm_group": {
            "arm_group_label": "P1101", 
            "arm_group_type": "Experimental", 
            "description": "P1101 50\u00b5g s.c. will be administered every 2 weeks in addition to preexisting imatinib treatment. In the absence of dose limiting toxicities after 12 weeks, the dose will be escalated to 100\u00b5g every 2 weeks.\nMaximum treatment duration will not expand 18 months."
        }, 
        "brief_summary": {
            "textblock": "In this phase I pilot study, it is planned to investigate the feasibility and safety of\n      adding an interferon therapy to an preexisting imatinib treatment in patients with chronic\n      phase chronic myeloid leukaemia. The participating patients have already reached a response\n      during their imatinib therapy (CCyR) but have still a detectable disease (no molecular\n      response MR 4.5 or better)."
        }, 
        "brief_title": "Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Phase Chronic Myeloid Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
                "Leukemia, Myeloid, Chronic-Phase"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients \u2265 18 years of age\n\n          -  BCR-ABL positive chronic myeloid leukaemia in chronic phase treated with imatinib as\n             first line therapy\n\n          -  CHR, CCyR after at least 18 months of imatinib treatment\n\n          -  Adequate organ function, defined as the following:\n\n               -  total bilirubin < 1.5 x ULN,\n\n               -  AST and ALT < 2.5 x ULN,\n\n               -  creatinine < 1.5 x ULN,\n\n               -  ANC > 1.5 x 109/L,\n\n               -  platelets > 100 x 109/L\n\n          -  Written, voluntarily signed informed consent\n\n        Exclusion Criteria:\n\n          -  CMR (molecular remission 4.5 or BCR-ABL transcripts undetectable)\n\n          -  Patient has received any other investigational treatment within 28 days before study\n             entry\n\n          -  Treatment with a second generation tyrosine kinase inhibitor (dasatinib, nilotinib)\n\n          -  ECOG performance status \u2265 3\n\n          -  Patients with a primary of a different histological origin than the study indication\n             (unless relapse-free interval is \u2265 5 years, except cervical carcinoma, basal cell\n             epithelioma or squamous cell carcinoma of the skin)\n\n          -  Evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated\n             respiratory, cardiac, hepatic or renal disease etc.)\n\n          -  Acute chronic infections\n\n          -  Known autoimmune disease (e.g. collagen disease, polyarthritis, immune\n             thrombocytopenia, thyroiditis, psoriasis, lupus nephritis or any other autoimmune\n             disorder)\n\n          -  Female patients who are pregnant or breast-feeding\n\n          -  Known diagnosis of HIV"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01933906", 
            "org_study_id": "AGMT_CML 1", 
            "secondary_id": "2013-000115-24"
        }, 
        "intervention": {
            "arm_group_label": "P1101", 
            "intervention_name": "P1101", 
            "intervention_type": "Drug", 
            "other_name": "PEG-Proline-Interferon alpha-2b"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferon Alfa-2b", 
                "Interferons", 
                "Reaferon", 
                "Imatinib"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "CML", 
            "Chronic myeloid leukemia", 
            "Chronic myeloid leukaemia", 
            "PEG-Proline-Interferon-alpha 2b", 
            "Interferon", 
            "P1101", 
            "Imatinib"
        ], 
        "lastchanged_date": "August 29, 2013", 
        "location": [
            {
                "contact": {
                    "email": "sonja.burgstaller@klinikum-wegr.at", 
                    "last_name": "Sonja Burgstaller, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Wels", 
                        "country": "Austria", 
                        "state": "Ober\u00f6sterreich", 
                        "zip": "4600"
                    }, 
                    "name": "Klinikum Wels-Grieskirchen GmbH, IV. Interne Abteilung"
                }, 
                "investigator": {
                    "last_name": "Sonja Burgstaller, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "r.greil@salk.at", 
                    "last_name": "Richard Greil, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Salzburg", 
                        "country": "Austria", 
                        "zip": "5020"
                    }, 
                    "name": "Universit\u00e4tsklinikum der PMU Salzburg, Universit\u00e4tsklinik f\u00fcr Innere Medizin III"
                }, 
                "investigator": {
                    "last_name": "Richard Greil, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1 Study to Evaluate the Feasibility and Efficacy of the Addition of P1101 (PEG-Proline-Interferon Alpha-2b) to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response (MR 4.5 or BCR-ABL Transcripts Not Detectable)", 
        "overall_contact": {
            "email": "d.wolkersdorfer@agmt.at", 
            "last_name": "Daniela Wolkersdorfer, PhD", 
            "phone": "+43 664 1422504"
        }, 
        "overall_official": {
            "affiliation": "Klinikum Wels-Grieskirchen GmbH", 
            "last_name": "Josef Thaler, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Austria: Agency for Health and Food Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective is to determine the safety and tolerability of the addition of P1101 to the pre-study established dose of imatinib.", 
            "measure": "Number and seriousness of adverse events to evaluate safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "30 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01933906"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Secondary objective is to determine the rate of achievement of \u2265 1 log reduction from the initial BCR-ABL transcript level at study entry and the achievement of molecular remission 4.5 or undetectable BCR-ABL transcripts.", 
            "measure": "Efficacy (Number of patients achieving an improvement of remission status)", 
            "safety_issue": "No", 
            "time_frame": "30 months"
        }, 
        "source": "Arbeitsgemeinschaft medikamentoese Tumortherapie", 
        "sponsors": {
            "collaborator": {
                "agency": "AOP Orphan Pharmaceuticals AG", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Arbeitsgemeinschaft medikamentoese Tumortherapie", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}